MENU
Abstract Patients who are diagnosed with MRONJ while being treated with bone modifying agents(BMAs) at oncologic doses, there is insufficient evidence to support or refute the discontinuation of BMAs. Administration of the BMA may be deferred at the discretion of…
We use cookies to make your website experience better. By accepting this notice and continuing to browse our website you confirm you accept our Terms of Use & Privacy Policy.
read more >>